Table 4.

Topics rated as being "very important" or "quite important".

Topics	Percentage of RECs reporting
The use of placebo controlled trials	100% (10/10)
Determination of methods to reduce risk	92% (11/12)
The interpretation of pre-clinical studies	91% (10/11)
Determination of risks in research	91% (10/11)
Assessment of benefits to participants and society	90% (9/10)
Scientific design issues in clinical trials	90% (9/10)
Monitoring and oversight of approved studies	90% (9/10)
Assessment of cultural sensitivity for informed consent	82% (9/11)
Assessment of understanding of informed consent	80% (8/10)
Access to benefits after the trial is over	78% (7/9)
Determination of appropriate subject selection in vulnerable populations	75% (9/12)
Community participation	67% (6/9)
Social and behavioral studies	75% (9/12)
Privacy and confidentiality	70% (7/10)